Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China

OBJECTIVE: The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Yunchun, Xu, Yuan, Liao, Li, Zhou, Yujie, Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432650/
https://www.ncbi.nlm.nih.gov/pubmed/37586861
http://dx.doi.org/10.1136/bmjopen-2023-072106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432650/
https://www.ncbi.nlm.nih.gov/pubmed/37586861
http://dx.doi.org/10.1136/bmjopen-2023-072106

Ejemplares similares